Prindamine
Prindamine is a noradrenaline transporter inhibitor with very weak anticholinergic and serotonin (5-HT) uptake inhibiting effects. Prindamine blocks noradrenaline uptake, increasing synaptic availability of noradrenaline in the brain. Prindamine decreases rapid eye movement sleep (REMS) in cats. Prindamine initially increases the proportion of time spent in active wakefulness in cats.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 21489-22-5
- Formel: C21H27N
- Molecular Weight:293.45
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
In Vivo
Propranolol (HY-B0573B) reverses the increase in active wakefulness, Prazosin (HY-B0193) exacerbates the reduction in REMS and decreases deep slow-wave sleep, and Yohimbine (HY-N0127) enhances active wakefulness without altering the reduction in REMS[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Domestic cats (male, 1-3 years old, 3.0-4.5 kg, with implanted EEG, EOG, and EMG electrodes)[1]
-
Dosage:0.5 mg/kg; 1.0 mg/kg; 5 mg/kg; 5 mg/kg + Yohimbine 1 mg/kg; 5 mg/kg + Phentolamine 10 mg/kg; 5 mg/kg + Prazosin 1 mg/kg; 5 mg/kg + Propranolol 5 mg/kg
-
Administration:i.p.; single dose
-
Result:Increased active wakefulness from a control mean of 20.9% to 31.3% of 16-h recording time.
Decreased rapid eye movement sleep from a control mean of 15.8% to 6.6%.
Lengthened rapid eye movement sleep latency from a control mean of 50 min to 291 min.
Did not alter percentages of light slow wave sleep or deep slow wave sleep.
Decreased rapid eye movement sleep at doses of 0.5 mg/kg and 1.0 mg/kg.
Increased active wakefulness to 38.4% when co-administered with Yohimbine 1 mg/kg.
Decreased drowsy wakefulness from 22.6% to 16.1% when co-administered with Yohimbine 1 mg/kg.
Maintained rapid eye movement sleep at 6.5% when co-administered with Yohimbine 1 mg/kg.
Partially antagonized prindamine-induced rapid eye movement sleep reduction, with rapid eye movement sleep at 10.7% when co-administered with Phentolamine 10 mg/kg.
Shortened rapid eye movement sleep latency to 155 min when co-administered with Phentolamine 10 mg/kg.
Restored deep slow wave sleep to control levels (27.3%) when co-administered with Phentolamine 10 mg/kg.
Increased active wakefulness to 37.9% and drowsy wakefulness to 31.6% when co-administered with Prazosin 1 mg/kg.
Further decreased rapid eye movement sleep to 2.2% when co-administered with Prazosin 1 mg/kg.
Lengthened rapid eye movement sleep latency to 354 min when co-administered with Prazosin 1 mg/kg.
Reduced deep slow wave sleep to 12.2% when co-administered with Prazosin 1 mg/kg.
Antagonized prindamine-induced active wakefulness increase, with active wakefulness at 17.9% when co-administered with Propranolol 5 mg/kg.
Increased drowsy wakefulness to 29.1% when co-administered with Propranolol 5 mg/kg.
Maintained rapid eye movement sleep at 5.6% when co-administered with Propranolol 5 mg/kg.
Restored deep slow wave sleep to control levels (29.8%) when co-administered with Propranolol 5 mg/kg.
Chemical Information
-
CAS. Nr. 21489-22-5
-
Molecular Weight 293.45
-
Formel C21H27N
-
SMILES
C=1C=CC(=CC1)C2(C=3C=CC=CC3C(C)(C)C2)CCCNC
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Prindamine Related Classifications
HY-124492 Related Classifications
Powered by Bioz